HOME >> MEDICINE >> NEWS
FOSRENOL significantly reduces tablet burden for end-stage renal patients with hyperphosphatemia

-- Additional Data Reveal that Higher Initial Doses of FOSRENOL Result in More Rapid Control of Mean Serum Phosphorus than Lower Initial Doses --

Chicago, IL (April 20, 2006)-According to data presented today at the National Kidney Foundation's (NKF) 2006 clinical meeting in Chicago, IL, a conversion to the non-calcium phosphate binder FOSRENOL (lanthanum carbonate) from other phosphate binder therapies provides continued mean serum phosphorus control for end-stage renal disease (ESRD) patients with hyperphosphatemia, while significantly reducing their daily tablet burden and the total daily dose of phosphate binder medication.

This naturalistic ("real world"), large-scale phase IV, open-label, multicenter trial (n=2,520), was designed to evaluate efficacy, patient and physician satisfaction, and daily dose and tablet burden compared with previous phosphate binder therapy. In addition to reducing tablet burden, changing to FOSRENOL from other therapies resulted in significant improvements in both patient and physician satisfaction with phosphate binder therapy. Both patients and physicians preferred FOSRENOL (lanthanum carbonate) over sevelamer hydrochloride (HCI) and calcium-based phosphate binders in a naturalistic study.

"Successfully managing hyperphosphatemia is a challenge for most ESRD patients due to the exceedingly restrictive diet they must follow and the high tablet burden associated with traditional phosphate binder therapies," said Nirupama Vemuri, MD, South Florida Nephrology Group, Coral Springs, FL. "By significantly reducing phosphate binder tablet burden, FOSRENOL may help improve patient compliance, as well as clinical outcomes for patients with hyperphosphatemia."

At baseline, 52 percent of physicians expressed overall satisfaction with their phosphate binder therapies compared with 84 percent following 12 weeks of treatment with FOSRENOL (p<0.0001). Among patients who completed 12 weeks of treatment (n=1,862),
'"/>


21-Apr-2006


Page: 1 2 3

Related medicine news :

1. Higher dose formulation of FOSRENOL approved to reduce serum phosphorus in esrd patients
2. Trial stops after stroke and mortality significantly reduced by blood
3. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
4. Full-term, low-birth-weight babies at significantly greater risk for early respiratory symptoms
5. Once-yearly treatment significantly reduces bone fractures in women with postmenopausal osteoporosis
6. New study: Pine bark significantly reduces endometriosis
7. Regular acupressure can significantly reduce agitated behavior in dementia
8. Health care expenditures significantly higher for children with obesity
9. Women with rheumatoid arthritis have significantly less chance of remission than men
10. Younger African American women at significantly higher risk for breast cancer
11. Computer-driven system reduces patient mechanical ventilation time significantly

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2019)... CARDIFF BY THE SEA, Calif. (PRWEB) , ... ... ... Prickly Pear fruit, trademarked as Tex-OE, Opuntia Mesocarp Extract®, provides protection from disruptions ... amazing extract, effective at countering the menace of Jet Lag, is available in ...
(Date:12/4/2019)... ... December 04, 2019 , ... Healthcare Real Estate Insights™ ... national awards dedicated to recognizing excellence in the areas of healthcare real estate ... nine different categories during the GlobeSt Healthcare Conference today in Scottsdale, Ariz. , ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... UNC Health ... easily find their way around the campuses of UNC Medical Center in Chapel Hill ... two hospitals, parking garages, clinics and more. , The free interactive app, developed by ...
(Date:12/2/2019)... YORK (PRWEB) , ... December 02, 2019 , ... More ... year at midnight on December 31. While many people spend their tax-free funds throughout ... ball drops on New Year’s Eve. In an effort to help account holders use ...
(Date:12/2/2019)... ... December 02, 2019 , ... Interim HealthCare Inc. , a ... the 2019 Workforce: Optimas Awards . Selected for its multi-pronged approach to building ... help combat the nation’s caregiver shortage. By 2025, the U.S. will need to hire ...
Breaking Medicine News(10 mins):
(Date:12/4/2019)... FOREST, Calif. (PRWEB) , ... December 04, 2019 ... ... technology company providing healthcare professionals with minimally invasive technologies to treat chronic pain ... procedures performed with the Tenex Health TX® technology. , Dr. Bernard ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... ... physicians to better manage their COPD patient’s symptoms, joined forces nearly a year ... patients immediate access to in-person care at times when the attention is most ...
(Date:12/2/2019)... , ... December 02, 2019 , ... ... of A Mission for Michael, an intensive mental health facility, announced it has ... oversee client relations, business development and national advocacy efforts. , "We are proud ...
Breaking Medicine Technology:
Cached News: